Memo Therapeutics AG’s CHF20 Million Additional Series C Financing Round

Marco Zingaro Europe Legal Chronicle
Tagged:

VISCHER advised Ysios Capital and Kurma Partners.Memo Therapeutics AG, a late-stage biotech company developing a best-in-class BKV-neutralizing anti-body for BKV infection in kidney transplantation, raised CHF20…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:

Author: Marco Zingaro

…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here